[Wilson's disease: physiopathological, clinical and therapeutic considerations].
Pérez-Aguilar
F
F
Servicio de Medicina Digestiva. Hospital La Fe. Valencia. España.
D000251:Adenosine Triphosphatases / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D000293:Adolescent; D000328:Adult; D001480:Basal Ganglia Diseases / Q000209:etiology; D001921:Brain / Q000473:pathology; D027682:Cation Transport Proteins / Q000172:deficiency / Q000235:genetics / Q000502:physiology; D002570:Ceruloplasmin / Q000172:deficiency; D002614:Chelating Agents / Q000627:therapeutic use; D015913:Chelation Therapy; D003300:Copper / Q000378:metabolism; D000073840:Copper-Transporting ATPases; D003886:Descemet Membrane / Q000737:chemistry / Q000473:pathology; D005260:Female; D005808:Genes, Recessive; D006521:Hepatitis, Chronic / Q000209:etiology; D006527:Hepatolenticular Degeneration / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D001523:Mental Disorders / Q000209:etiology; D008875:Middle Aged; D008982:Molybdenum / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications; D011379:Prognosis; D011993:Recombinant Fusion Proteins; D014266:Trientine / Q000627:therapeutic use; D015032:Zinc / Q000627:therapeutic use
D027682:Cation Transport Proteins; D002614:Chelating Agents; D011993:Recombinant Fusion Proteins; D003300:Copper; D008982:Molybdenum; C020809:tetrathiomolybdate; D002570:Ceruloplasmin; D000251:Adenosine Triphosphatases; C081184:ATP7A protein, human; D000073840:Copper-Transporting ATPases; D010396:Penicillamine; D015032:Zinc; D014266:Trientine